Melasma, an acquired chronic skin hypermelanosis, commonly manifests as symmetrical brown-gray patches on the face and may significantly affect the self-esteem and quality of life of patients. 1 The pathogenesis of melasma involves complex dynamic epidermaldermal interaction among various cell types, inflammation, oxidative stress, and photodamage. [2][3][4] All factors significantly contribute to its development. Melasma treatment is challenging and presents frequent relapses. Conventional treatments targeting only melanin synthesis have shown mixed results. 5,6 New treatments that act at various melanin synthesis levels to reduce free radicals and inflammation have been developed 7,8 ; however, the primary treatment is still topical lightening agents targeting tyrosinase, a rate-limiting enzyme in the process of melanogenesis. The most common topical tyrosinase inhibitors used are hydroquinone, arbutin, azelaic acid,

No abstract